Humacyte is trading 12.68% down now at $0.62 after its August 12, 2026 second-quarter results missed consensus expectations.
- Revenue was $410,000 versus $1.138 million estimated; adjusted loss per share was $0.16 versus $0.10 expected.
- Symvess sales improved year over year and dialysis results were encouraging, but continued losses appear to outweigh those positives.
- Despite broadly higher major indexes, the earnings miss was the clearest catalyst; no specific 2026 revenue or EPS guidance heightened commercial-ramp uncertainty.